Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial

Raghu, Ganesh; Million-Rousseau, Rachel; Morganti, Adele; Perchenet, Loic; Behr, Juergen

doi:10.1183/09031936.00104612

Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial

Raghu G., Million-Rousseau R., Morganti A., Perchenet L., Behr J.

EUROPEAN RESPIRATORY JOURNAL, cilt.42, sa.6, ss.1622-1632, 2013 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 42 Sayı: 6
Basım Tarihi: 2013
Doi Numarası: 10.1183/09031936.00104612
Dergi Adı: EUROPEAN RESPIRATORY JOURNAL
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1622-1632
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Ankara Üniversitesi Adresli: Hayır

Özet

Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis.